Alembic Pharmaceuticals Ltd has received EIR from USFDA for the inspection carried out by them at our Solid Oral Formulation Facility (F-4) at Jarod, Vadodara.
The Board of Directors of Alembic Pharmaceuticals Limited, have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023 at its board meeting.
Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application Brimonidine Tartrate Ophthalmic Solution, 0.15%.
Alembic Pharmaceuticals Limited has successfully completed the Brazilian Health Regulatory Agency GMP audit at API-III Facility at Karakhadi without any observations for its 56 APIs.
The USFDA has conducted an inspection at Alembic Pharmaceuticals Injectable and Ophthalmic Facility - F-3 located at Karkhadi from 16th March, 2023 to 24th March, 2023 and issued Form 483 with 2 minor procedural observations.